Clinical Trials Browser

Phase NA × Brentuximab Vedotin × 90 days × Clear all

NCT01868451 2026-06-04

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Phase NA Completed

Hodgkin Disease